Dr. Colace is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
700 Childrens Dr
Columbus, OH 43205Phone+1 614-722-3552Fax+1 614-722-3699
Education & Training
- Vanderbilt University Medical CenterFellowship, Clinical Pharmacology, 2010 - 2013
- Vanderbilt UniversityMS, Clinical Investigation, 2010 - 2012
- Vanderbilt University Medical CenterFellowship, Pediatric Hematology/Oncology, 2009 - 2012
- University of Alabama Medical CenterResidency, Pediatrics, 2006 - 2009
- Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 2006
Certifications & Licensure
- OH State Medical License 2013 - 2025
- TN State Medical License 2009 - 2014
- AL State Medical License 2008 - 2009
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
- American Board of Clinical PharmacologyClinical Pharmacology
Clinical Trials
- PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Start of enrollment: 2019 Feb 12
- The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study Start of enrollment: 2015 Oct 01
Roles: Contact
Publications & Presentations
PubMed
- COVID-19 Disease in Children With ALL Receiving Maintenance Therapy: Do Not Discount the Risk.Alissa R Kahn, Elizabeth S Davis, Chen Dai, Caroline V Caudill, Isaac Martinez
JCO Oncology Practice. 2024-12-01 - Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium.Eric S Schafer, Teresa Rushing, Kristine R Crews, Colleen Annesley, Susan I Colace
Journal of the National Cancer Institute. 2024-11-01 - 8 citationsClinical Targeted Next-Generation Panel Sequencing RevealsAmplification Is a Poor Prognostic Factor in Osteosarcoma.Amanda E Marinoff, Liam F Spurr, Christina Fong, Yvonne Y Li, Suzanne J Forrest
JCO Precision Oncology. 2023-03-01
Professional Memberships
- American Society of Clinical Pharmacology and TherapeuticsMember
- Children's Oncology GroupMember
Other Languages
- Spanish
External Links
- ORCIDhttps://orcid.org/0000-0003-3868-3655
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: